Skip to main content
. Author manuscript; available in PMC: 2023 May 15.
Published in final edited form as: Sci Immunol. 2022 Oct 14;7(76):eabo3420. doi: 10.1126/sciimmunol.abo3420

Figure 1: Graft-versus-tumor effects were subverted after alloBMT in myeloma-bearing but not leukemia-bearing recipients.

Figure 1:

C57Bl/6 (B6) recipients injected with Vk*MYC myeloma (MM-bearing; D-14) or MLL-AF9 (AML-bearing; D0) were lethally irradiated and transplanted with 5 × 106 BM with 0.5 × 106 CD4+ + 0.5 × 106 CD8+ T cells from B6 (synBMT) or C3H.SW (alloBMT) donors. (A) Experimental schematic. (B) AML-bearing recipients were bled weekly to quantify the total number of circulating GFP+ AML cells and competing risk analysis was performed to determine risk of death due to acute myeloid leukemia (AML) or GVHD. n = 11/group from 2 experiments. Mann-Whitney U test for AML burden. (C) Experimental schematic. (D) MM-bearing recipients were monitored for tumor burden using M-band (G/A). M-bands were modeled to calculate a predictive rate of tumor growth (solid line), with shaded confidence intervals and M-band relapse threshold shown as dotted line. Competing risk analysis was performed to determine risk of death due to myeloma (MM) or graft-versus-host disease (GVHD). n = 20/group from 3 experiments. * p<0.05, ** p<0.01.